Cancer Drug Development To See “Vast Improvements” In Speed – Thompson
Executive Summary
HHS Secretary Thompson vows to make "vast improvements" in expediting oncology drug development using the FDA/National Cancer Institute Interagency Oncology Task Force
You may also be interested in...
ClinicalTrials.gov Noncompliance Remains An FDA Concern
The pharmaceutical industry's failure to list cancer trial information on ClinicalTrials.gov remains a concern to FDA, Oncology Drug Products Division Director Richard Pazdur, MD, said May 12
ClinicalTrials.gov Noncompliance Remains An FDA Concern
The pharmaceutical industry's failure to list cancer trial information on ClinicalTrials.gov remains a concern to FDA, Oncology Drug Products Division Director Richard Pazdur, MD, said May 12
CMS/NCI Will Test Model For Evidence-Based Reimbursement
A collaboration between the National Cancer Institute and the Centers for Medicare & Medicaid Services will examine cancer therapies as a model for evidence-based reimbursement, NCI Director Andrew von Eschenbach, MD, told the Milken Institute Global Conference in Los Angeles April 26-27